S. 2099 (119th)Bill Overview

Restore Prescription Drugs Discount Act

Health|Health
Sponsor
Cosponsors
Support
Republican
Introduced
Jun 17, 2025
Discussions
Bill Text
Current stageCommittee

Read twice and referred to the Committee on the Judiciary.

Introduced
Committee
Floor
President
Law
Congressional Activities
01 · The brief
Plain-English summaryWhat this bill actually does

This bill would repeal the Robinson–Patman Act of 1936 in its entirety. The Robinson–Patman Act is a federal antitrust statute that, among other things, prohibits certain forms of price discrimination by sellers of goods.

Why people may split

Whether repeal primarily benefits consumers via lower negotiated prices (conservative view) or disproportionately benefits large purchasers/intermediaries at the expense of small retailers and some consumers (liberal view).

Watch point

Relative to its intended legislative type, this bill is legally precise about what is being changed (the repeal of the Robinson-Patman Act) but provides minimal contextual, implementation, fiscal, or oversight detail.

This bill would repeal the Robinson–Patman Act of 1936 in its entirety.

The Robinson–Patman Act is a federal antitrust statute that, among other things, prohibits certain forms of price discrimination by sellers of goods.

Repeal would remove that statutory prohibition and any amendments made by that Act, without adding replacement provisions or regulatory language in this bill text.

Passage35/100

On content alone, a straight repeal of a long‑standing antitrust statute is politically and substantively significant despite the bill's brevity. The proposal lacks compromise mechanisms, invites organized opposition from small businesses and consumer advocates, and has uncertain economic effects that would draw scrutiny from regulators and committees. While it could attract powerful industry backers, those factors make enactment unlikely without broader legislative packaging or negotiation.

CredibilityPartially aligned

Relative to its intended legislative type, this bill is legally precise about what is being changed (the repeal of the Robinson-Patman Act) but provides minimal contextual, implementation, fiscal, or oversight detail.

Contention75/100

Whether repeal primarily benefits consumers via lower negotiated prices (conservative view) or disproportionately benefits large purchasers/intermediaries at the expense of small retailers and some consumers (liberal view).

02 · What it does

Who stands to gain, and who may push back.

Likely benefits vs burdens50% / 50%
Federal agencies · ManufacturersLocal governments · Consumers

These are examples from the analysis, not a ranked list of the most-affected groups.

Likely helped
  • Federal agenciesRemoves a federal statutory constraint on price discrimination, which supporters say would enable manufacturers and sup…
  • ManufacturersReduces regulatory compliance costs and potential litigation exposure associated with Robinson–Patman claims for manufa…
  • Potential benefitEnables more flexible pricing arrangements and contracting practices (e.g., tailored discounts, volume-based deals) tha…
Likely burdened
  • Local governmentsCritics say repeal could enable larger buyers to secure exclusive or deeper discounts that small or independent pharmac…
  • ConsumersOpponents argue the change could facilitate discriminatory contracting or exclusionary practices (for example, favored…
  • Potential burdenRepeal would eliminate a statutory cause of action specific to price discrimination, which critics say reduces legal re…
03 · Why people split

Why the argument around this bill splits.

Whether repeal primarily benefits consumers via lower negotiated prices (conservative view) or disproportionately benefits large purchasers/intermediaries at the expense of small retailers and some consumers (liberal vi…
Progressive20%

A mainstream liberal/left-leaning observer would likely view this bill with concern.

They would see repeal of Robinson–Patman as removing protections against price discrimination that historically helped small businesses and independent retailers, and worry about downstream harms to small pharmacies, rural providers, and consumers who lack bargaining power.

They would also be skeptical that repeal will automatically lower prescription costs for end users and worry discounts could flow preferentially to large purchasers or intermediaries rather than patients.

Likely resistant
Centrist55%

A pragmatic moderate would weigh potential pro-competitive flexibility against the risk of hurt small businesses and opaque discounting.

They would note that Robinson–Patman has been less actively enforced in recent decades and that modern competition issues often involve PBMs, insurers, and vertical consolidation rather than simple price discrimination among retailers.

They would likely be open to repeal if accompanied by measures to protect small sellers and to ensure discounts benefit consumers rather than only intermediaries.

Split reaction
Conservative90%

A mainstream conservative would generally view the repeal positively as a deregulatory, pro-market move that removes an old restriction on price flexibility.

They are likely to argue that allowing manufacturers to set different prices freely promotes competition, enables negotiated discounts, and could help lower costs for large purchasers and ultimately consumers.

They would typically oppose keeping an economy-wide price-discrimination prohibition that can inhibit innovative contracting and discounts.

Leans supportive
04 · Can it pass?

The path through Congress.

Introduced

Reached or meaningfully advanced

Committee

Reached or meaningfully advanced

Floor

Still ahead

President

Still ahead

Law

Still ahead

Passage likelihood35/100

On content alone, a straight repeal of a long‑standing antitrust statute is politically and substantively significant despite the bill's brevity. The proposal lacks compromise mechanisms, invites organized opposition from small businesses and consumer advocates, and has uncertain economic effects that would draw scrutiny from regulators and committees. While it could attract powerful industry backers, those factors make enactment unlikely without broader legislative packaging or negotiation.

Scope and complexity
86%
Scopesweeping
24%
Complexitylow
Why this could stall
  • The bill text provides no cost estimate or analysis of likely economic effects; the magnitude and distribution of impacts on prices, competition, and consumers are therefore unclear.
  • Political coalition dynamics are unknown from the text: which industry groups, state officials, or congressional actors would actively support or oppose the repeal, and whether the bill would be offered alone or as part of a larger package.
05 · Recent votes

Recent votes on the bill.

No vote history yet

The bill has not accumulated any surfaced votes yet.

06 · Go deeper

Go deeper than the headline read.

Included on this page

Whether repeal primarily benefits consumers via lower negotiated prices (conservative view) or disproportionately benefits large purchasers…

On content alone, a straight repeal of a long‑standing antitrust statute is politically and substantively significant despite the bill's br…

Unlocked analysis

Relative to its intended legislative type, this bill is legally precise about what is being changed (the repeal of the Robinson-Patman Act) but provides minimal contextual, implementation, fiscal, or oversight detail.

Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.

Perspective breakdownsPassage barriersLegislative design reviewStakeholder impact map
Open full analysis